Zobrazeno 1 - 10
of 16
pro vyhledávání: '"David Arias Ron"'
Autor:
Carmen M Labandeira, Arturo Fraga-Bau, David Arias Ron, Elena Alvarez-Rodriguez, Pablo Vicente-Alba, Javier Lago-Garma, Ana I Rodriguez-Perez
Publikováno v:
Neural Regeneration Research, Vol 17, Iss 8, Pp 1652-1658 (2022)
In the last decade, attention has become greater to the relationship between neurodegeneration and abnormal insulin signaling in the central nervous system, as insulin in the brain is implicated in neuronal survival, plasticity, oxidative stress and
Externí odkaz:
https://doaj.org/article/ab13aa1958d242638c41be8cc74e1068
Autor:
Nieves Martínez-Lago, Ana Fernández-Montes, Marta Covela, Elena M. Brozos, Juan De la Cámara, José C. Méndez Méndez, Mónica Jorge-Fernández, Antía Cousillas Castiñeiras, Cristina Reboredo, David Arias Ron, María L. Pellón Augusto, Paula González Villarroel, Begoña Graña, Mercedes Salgado Fernández, Alberto Carral Maseda, Francisca Vázquez Rivera, Sonia Candamio Folgar, Margarita Reboredo López, On behalf of the Galician Research Group on Digestive Tumors (GITuD)
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Outcomes are poorer in metastatic colorectal cancer (mCRC) patients with BRAF V600E mutations than those without it, but the effect of these mutations on treatment response is unclear. This real-world study assessed the effects of
Externí odkaz:
https://doaj.org/article/0205a0ed5fdf486f96be2430c7159205
Autor:
David Arias Ron, Carmen M. Labandeira, Soledad Cameselle García, Jesús García Mata, Mercedes Salgado Fernández
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 1, Pp 69-75 (2020)
In a patient who had been diagnosed in 2006 with appendiceal adenocarcinoma with peritoneal metastases after an incomplete surgery, palliative chemotherapy was administered. First-line treatment with 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX
Externí odkaz:
https://doaj.org/article/16e9115873894ca895238c1f37720e24
Autor:
Luis E. Raez, Amanda Nogueira, Edgardo S. Santos, Ricardo Sales dos Santos, Juliana Franceschini, David Arias Ron, Mark Block, Nise Yamaguchi, Christian Rolfo
Publikováno v:
Journal of Global Oncology, Vol 4, Pp 1-10 (2018)
Lung cancer is the deadliest cancer worldwide and is of particular concern for Latin America. Its rising incidence in this area of the world poses myriad challenges for the region’s economies, which are already struggling with limited resources to
Externí odkaz:
https://doaj.org/article/9c3b0bb5fe9949b4b4798e1c6b6ef743
Autor:
David Arias Ron, Carmen M. Labandeira, María Carmen Areses Manrique, Paula Sampedro Domarco, Ihab Abdulkader, Jesús García-Mata, Christian Rolfo, Diego González-Rivas, Jose Luis Fírvida
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
In a patient who had been diagnosed of located squamous cell lung carcinoma, pneumonectomy, and adjuvant chemotherapy were performed. Brain recurrence and subsequent lung metastatic disease were uncontrolled by neurosurgery, holocranial radiotherapy,
Externí odkaz:
https://doaj.org/article/0227a4fb32734cf9aced213326d3f9b3
Autor:
Soledad Cameselle Garcia, Mercedes Salgado Fernández, Jesús García Mata, David Arias Ron, Carmen M. Labandeira
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 13, Iss 1, Pp 69-75 (2020)
Case Reports in Oncology, Vol 13, Iss 1, Pp 69-75 (2020)
In a patient who had been diagnosed in 2006 with appendiceal adenocarcinoma with peritoneal metastases after an incomplete surgery, palliative chemotherapy was administered. First-line treatment with 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::857a8a7dbd9c2aecc7e885d9f5fe40c7
https://doi.org/10.1159/000505237
https://doi.org/10.1159/000505237
Autor:
R Vera, N G Cid, Ana Fernández Montes, M Á Núñez, Carmen M. Labandeira, David Arias Ron, Jesús García Mata, M C Areses Manrique
Publikováno v:
Clinical and Translational Oncology. 22:1205-1215
Over the last 2 decades, the standard fluoropyrimidine-based chemotherapy backbone for metastatic colorectal cancer has been complemented by the addition of novel biological agents, achieving impressive increases in 5-year survival rates. Nonetheless
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::921406ff95155bbd961bafd4166f909a
https://doi.org/10.1007/s12094-019-02267-9
https://doi.org/10.1007/s12094-019-02267-9
Autor:
Marika Rasschaert, Ranee Mehra, Katherine A. Scilla, Christian D. Rolfo, Hans Prenen, Patrick Pauwels, David Arias Ron, Alessandro Russo
Publikováno v:
JCO Precision Oncology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ade639477e108289df983bedcb8361e
https://doi.org/10.1200/po.19.00243
https://doi.org/10.1200/po.19.00243
Autor:
Nieves Martinez Lago, Ana Fernández Montes, Marta Covela Rúa, Elena M. Brozos Vázquez, Juan C. De la Cámara Gómez, Jose C. Méndez Méndez, Mónica Jorge Fernández, Antía Cousillas Castiñeiras, Cristina Reboredo Rendo, David Arias Ron, Marta Carmona Campos, Yolanda Vidal Insua, Maria L. Pellón Augusto, Paula González Villarroel, Begoña Graña Suarez, Mercedes Salgado Fernández, Alberto Carral Maseda, Francisca Vázquez Rivera, Sonia Candamio Folgar, Margarita Reboredo López
Background Outcomes are poorer in metastatic colorectal cancer (mCRC) patients with BRAF V600E mutations than those without it, but the effect of these mutations on treatment response is unclear. This real-world study assessed the effects of antiangi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4516fdfd7ed86ceeb492a6f2d08d1f56
https://doi.org/10.21203/rs.3.rs-79440/v1
https://doi.org/10.21203/rs.3.rs-79440/v1
Autor:
Rocio Vilchez Simo, Maria Carmen Areses Manrique, María Rosario García Campelo, Cristina Azpitarte Raposeiras, Jose Muñoz Iglesias, Joaquín Martínez, Urbano Anido Herranz, F.J. Afonso, Natalia Fernández Núñez, David Arias Ron, Begoña Campos Balea, Martin Lázaro Quintela, Juan Ruiz Bañobre, Jorge García González, Margarita Amenedo Gancedo, Lucía Santomé Couto, José Luis Fírvida Pérez, Joaquin Casal Rubio, Jesús García Mata, Guillermo Alonso-Jaudenes Curbera, Iria Carou Frieiro
Publikováno v:
Journal of geriatric oncology. 12(3)
Background Nivolumab is an anti PD1 immunotherapy drug approved for advanced Non-Small Cell Lung Cancer (NSCLC) patients who previously received at least one prior line of treatment. Older patients are often not represented in clinical trials and dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc8f0359c9eb9f002de01c36c87004c8
https://pubmed.ncbi.nlm.nih.gov/33357975
https://pubmed.ncbi.nlm.nih.gov/33357975